Abstract. The low percentage of human mesenchymal stem cells (hMSCs) in bone marrow necessitates their in vitro expansion prior to clinical use in regenerative medicine. We evaluated the effect of long-term culture of hMSCs on telomere length and transformation capacity by TERT transfection. hMSCs were isolated from the bone marrow aspirates of 24 donors and cultured with fibroblast growth factor-2 (FGF-2). Six cell lines with >500 population doubling levels were considered immortalized. TERT was transfected into two of the six lines for a comparison of telomere length, telomerase activity, differential capacity, colony formation capacity in soft agar and tumorigenicity in immunodeficient (NOD-SCID) mice. hMSC lines exhibited elongated telomeres without the activation of telomerase and retained multi-lineage differentiation potential upon chondrogenic or adipogenic differentiation, while non-immortalized hMSCs showed a marked reduction in telomere length in the differentiation process. Immortalized hMSCs showed anchorage-independence and formed tumors in NOD-SCID mice. Histologically, these tumors consisted of differentiated cells such as fat tissue and cartilage. Two TERTtransfected hMSC lines showed high rates of tumor formation in NOD-SCID mice. These tumors were histologically similar to teratocarcinoma without differentiated cells. These cells may provide a model for the origin of cancer stem cells from adult stem cells, and indicate the possibility that telomerase activation has a major role in the malignant transformation of human stem cells. These data suggest that adult hMSCs have a potential for neoplastic transformation and have implications for the use of hMSCs in tissue engineering and regenerative medicine.
Introduction
Stem cells in various adult tissues play an important role in the regeneration of damaged tissue and maintenance of homeostasis in the tissues in which they reside. Human mesenchymal stem cells (hMSCs) are of great interest in regenerative medicine because they have the potential to differentiate into a variety of cells such as osteoblasts, adipocytes, chondrocytes, myocytes, and probably neuronal cells (1) (2) (3) (4) (5) . Because of these properties, hMSCs might be a potential resource for future cell therapy. The goal of this study is to establish clinical cell lines with long life spans that retain their parental properties. However, clinical application has been difficult due to problems with retaining enhanced viability during storage, isolating cell populations with specific criteria, and expanding an in vitro system to obtain a sufficient number of cells without affecting their genomic characteristics and differentiation properties.
At present, there is very little evidence of whether changes in these properties occur during expansion. Normal hMSCs have a limited replicative capacity of at most 40-to 50-population doubling levels (PDL). The clinical use of hMSCs requires a large number of cells. Fibroblast growth factor-2 (FGF-2) increases PDL in hMSC monolayer cultures while preserving the differentiation potential (6, 7) . These FGF-2 expanded MSCs [FGF(+) hMSCs] exhibited long telomeres without upregulation of telomerase activity. Then, to elucidate the function of telomerase in hMSCs, we transfected TERT in these FGF(+) hMSC cell lines. In this study, we report on the immortalization of hMSCs by ALT (alternative lengthening of telomeres) and the neoplastic activity of these immortalized hMSCs following TERT transfection. The results indicate that immortalization might be regulated by ALT and that telomerase activation might be correlated with malignant transformation in hMSCs.
Materials and methods

Cell lines and TERT transfection.
Human mesenchymal stem cells were isolated from bone marrow (BM) aspirates of 24 human donors (16 men and 8 women, from 16 to 64 years of age) after obtaining informed consent as previously described (7 concentration 1 ng/ml; r&D Systems Inc., Minneapolis, MN, USA). After again reaching confluence, the cells were reseeded under the same conditions. Six samples proliferated for >500 PDL. These cells were transfected with the TErT expression plasmid hTERTn2 (provided by professor F. Ishikawa). hMSCs were transfected by using TransIT ® -LT1 Reagent (Mirus Bio Corp., Madison, WI, USA) with 2 µg of hTERTn2 linearized with NruI or with the vector plasmid linearized. G418 (Wako, Osaka, japan) (300 µg/ml) was added to the medium after 24 h to select for clones harboring the transfected gene. G418 selection was continued for at least 1 month in exponentially growing cultures. hMSCs and TERT-transfected hMSCs were collected at various PDLs using trypsin followed by a rinse with PBS and were stored at -80˚C.
Telomere length analysis. Telomere length was estimated using the length of terminal restriction fragments (TRFs) as measured by Southern blot analysis (8, 9) . Genomic DNA was isolated using proteinase k followed by phenol/chloroform extraction. Extracted DNA was completely digested with HinfI, electrophoresed in a 0.6% agarose gel (2 µg/lane), transferred to a nitrocellulose membrane, and hybridized with 5'-end [ 32 p]-labeled (TTAGGG) 4 . The length of the peak signals measured by the Bioimage Analyzer, BAS-2000 (Fuji film, kanagawa, japan) was estimated as the length of TrFs. Digested DNA was also subjected to pulse-field gel electrophoresis for the evaluation of long TRFs.
Telomere length was also measured by a fluorescence in situ hybridization (FISH) technique known as TeloFISH. TeloFISH was performed using a fluorescein isothiocyanate (FITC)-labeled peptide nucleic acid (PNA) probe specific for (TTAGGG)n sequences (Telomere PNA FISH kit/FITC, Dako Cytomation Co., kyoto, japan). Briefly, hMSCs were treated with colcemid (10 µg/ml, Life Technologies) to prepare metaphase spreads and were pre-fixed with 2 ml freshly made fixative (3+1 v/v methanol/glacial acetic acid). After 10 min at room temperature, cells were centrifuged at 500 x g for 10 min. This pre-fix treatment was performed three times. The fixed cells were fixed to the slides, denatured at 80˚C for 3 min, and hybridized with the FITC-conjugated telomere pNA probe for 30 min. The slides were then rinsed and washed at 65˚C for 5 min and counterstained with DAPI.
Assay for telomerase activity and detection for TERT. Extraction of telomerase protein and evaluation of its activity were performed using the telomeric repeat amplification protocol (TrAP) (10, 11) . Briefly, 10 5 -10 6 cells were homogenized in CHAPS lysis buffer. After 30 min of incubation on ice, the levels of telomerase activity were measured using the TRApeze XL kit (Serological Co., Gaithersburg, MD, USA), which is a quantitative, fluorescently-labeled PCr system for the estimation of relative telomerase activity levels with the use of a PCr internal control. The levels of fluorescein and sulforhodamine in each PCr product were measured in a fluorescent plate reader (Wallac, perkin-Elmer, Wellesley, MA, USA). The level of telomerase activity, expressed in units of total product generated (TPG), was quantified by the ratio of the fluorescein intensity of the entire TRAp ladder in each sample (which was corrected with respect to the negative control) to the sulforhodamine intensity of the internal control (which was corrected with respect to background).
The expression levels of TERT in hMSCs were estimated by the reverse transcription-quantitative polymerase chain reaction. Total cellular RNA was extracted from tumor tissues by acid-guanidium-phenol chloroform method (12) . First strand complementary DNA (cDNA) was synthesized with reverse transcriptase and random primers using a High-Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA). An aliquot of the cDNA (equivalent to 20 ng total rNA) was subjected to real-time rT-PCr using the TaqMan Gene Expression Assay (Applied Biosystems) for TERT and Pre-Developed TaqMan Assay reagents (Applied Biosystems) for 18S as an internal control. Results of the three or more independent measurements were averaged, and the relative gene expression levels were calculated as ratios to 18S expression levels for each sample.
Induction of chondrogenic, adipogenic, and osteogenic differentiation. Chondrogenic adipogenic and osteogenic differentiation potential were measured in hMSCs and TERTtransfected hMSCs. A modified version of johnstone's pellet culture system was used to induce chondrogenesis. Cells (10 6 ) were placed in a 15-ml polypropylene tube (Greiner BioOne, Frickenhausen, Germany) and centrifuged. The pellet was cultured at 37˚C in a humidified atmosphere of 95% air and 5% CO 2 in 1 ml of chondrogenic medium containing highglucose DMEM (Invitrogen) supplemented with 10 ng/ml transforming growth factor (TGF)-β3 (Sigma), 10 -7 M dexamethasone (Sigma), 50 µg/ml ascorbic acid-2-phosphate sesquimagnesium salt (Sigma), 40 µg/ml L-proline (Nacalai tesque, kyoto, japan), ITS-A supplement (Invitrogen; 10 µg/ml insulin, 6.7 ng/ml sodium selenite, 5.5 µg/ml transferrin, 110 µg/ml sodium pyruvate), and 1.25 mg/ml bovine serum albumin (BSA, Sigma). Adipogenic differentiation was assessed by incubating cells with Adipogenic Induction Medium (Cambrex Bio Sciences, Walkersville, MD, USA) and maintained in hMSC Adipogenic Maintenance SingleQuots (Cambrex Bio Sciences) for 2-3 weeks. Adipocytes are recognized by the accumulation of lipid-containing vacuoles that stain red with Oil Red-O. Osteogenic differentiation was assessed by incubating the cells with DMEM-LG and 10% FBS supplemented with 0.1 µM dexamethasone, 10 µM β-glycerophosphate, and 50 µM ascorbate (all from Sigma-Aldrich) for 2-3 weeks. Cultures were stained with silver nitrate (von kossa's staining) to assess mineralization.
Colony formation assay with soft agar. Anchorage-dependency of the cells was evaluated by conventional colony formation assay with soft agar. Trypsinized cells (5x10 3 ) were resuspended in DMEM containing 10% FBS and 0.4% SeaPlaque GTG agarose (Bio-products) and poured onto bottom ager containing 10% FBS and 0.53% agarose in a 30-mm culture dish. After 21 days of culture at 37˚C with 5% CO 2 , colony number was evaluated with crystal violet staining.
Transplantation of hMSCs in immunocompromised non-obese diabetic (NOD)-SCID mice.
Tumor cells were resuspended in a 1:1 mixture of Matrigel (Becton-Dickinson) and serum-free medium (DMEM with 1% penicillin/streptomycin). A 100-µl suspension containing between 100 and 100000 cells was injected subcutaneously (s.c.) into the f lanks of 6-to 10-week-old male NOD/SCID immunodeficient mice obtained from CLEA Japan (Tokyo, Japan). If tumors developed, tumor cells were dispersed and subcutaneously injected into secondrecipient NOD-SCID mice. Animal studies were approved by the Institutional Animal Care and Use Committee (Hiroshima University IRB No. A06-43) and conducted according to the Institutional Guidelines of Hiroshima University.
A portion of each developed tumor was re-cultured in vitro under the same conditions as the original tumor cells. The remainder of the tumor was fixed in formalin for pathological examination. The expression of TERT was detected by immunohistochemistry using an affinity-purified polyclonal rabbit antibody against TErT (EST21A) (Alpha Diagnostic International, San Antonio, TX) as previously described (13).
Statistical analysis. The data are shown as the mean ± SEM. Fisher's exact test was used for 2x2 contingency tables.
Results
Culture of hMSCs. Since hMSCs cultured without FGF-2 [MSCs-FGF(-)] entered senescence after approximately 20
PDLs, these hMSCs were cultured with FGF-2 [MSCs-FGF(+): FGF-2-expanded hMSCs]. FGF-2 was added to the culture at a final concentration of 1 ng/ml; these cells achieved more than 100 PDLs, doubling four times over a 4-day period, and exhibited small spindle-shaped aspects (Fig. 1A) . It was these small spindle-shaped cells that had a high proliferation potential (Fig. 1B) . Among 24 hMSC clones cultured with FGF-2, 6 had high proliferative activity (>100 PDLs). These clones have approximately the same proliferative rate in DMEM with or without FGF-2, and were considered to be immortalized hMSC clones (Fig. 1C) .
TERT or vector alone was transfected into these 6 clones after 100 PDL. These cells, which were obtained after selection with 300 µg/ml of G418, were similar to pre-transfection cells in proliferative activity and morphology. The cell lines proliferated indefinitely (>1000 PDL) without major morphological changes after transfection with TERT ( Fig. 1B and C) . These cell lines were used in all subsequent analyses.
Telomere length and telomerase in hMSCs and TERTtransfected hMSCs. Southern blot analysis showed that immortalized hMSCs maintain relatively long telomeric lengths (>23 kb). Pulse-field electrophoresis confirmed that the length of these elongated telomeres was approximately 40 kb ( Fig. 2A) . TeloFISH analysis also detected long telomeres in these expanded hMSCs and TERT-transfected hMSCs (Fig. 2B) . However, there was no detectable telomerase activity in these hMSCs. Therefore, these findings suggest that long telomeres in hMSCs are maintained by a telomeraseindependent mechanism.
Telomere lengths in TERT-transfected hMSCs were similar to those in untransfected hMSCs. The TRAp assay detected telomerase activity in TERT-transfected hMSCs but none in vector-transfected cells. All six lines showed high telomerase activity (14.6-1349.2 TpG) at 1-month post-transfection. The six TERT-transfected hMSC clones were cultured for more than 100 PDLs before telomerase activity was measured again. Telomerase activity was diminished in four clones (0.2-1.31 TpG in hMSC lines #1, #2, #5, and #6) and retained in two (1761.3 and 965.3 TpG in hMSC lines #3 and #4, respectively). TERT expression was also detected in these 6 clones just after transfection using RT-pCR, but retained in only two clones (hMSC#3 and hMSC#4) (Fig. 3) . Among these 6 cell lines, we focused on the two clones with retained telomerase and TERT expression for the following examination.
In vitro differentiation potential in lineages of immortalized hMSC lines. hMSCs reportedly have an extensive potential to differentiate into multiple cell lineages including osteoblasts, chondrocytes, and adipocytes (14) . To evaluate the effect of TERT transfection on differentiation, each hMSC line was A B C stimulated in lineage-specific induction medium for 2-4 weeks (Fig. 4) . In adipocyte-specific culture medium, all of the cell lines accumulated lipid-rich vacuoles in their cytoplasm within 2 weeks, which were made evident by Oil Red-O staining. After 3 weeks in chondrocyte differentiation media, hMSCs and TERT-transfected hMSCs had metachromasia by TB and expression of type II collagen. After culturing cells as a micromass pellet for 21 days, the size of the TERT-transfected hMSCs was slightly smaller those of the parent hMSCs, but both had differentiated into cartilage (Fig. 4A ) and, both hMSCs and TERT-transfected hMSCs showed greater adipogenetic ability (Fig. 4B) . After 2 weeks in osteoblast induction medium, hMSCs and TERT-transfected hMSCs showed a marked increase in alkaline phosphatase expression (Fig. 4C) , an osteoblast marker TERT-transfected immortalized mesenchymal stem cell lines retained the ability to differentiate into three lineages, although among cell lines there were significant variations in response to lineage-specific induction.
TERT enhanced the colony-forming ability of hMSCs. The colony formation assay revealed that colony numbers formed in soft agar were highly correlated with TERT expression levels in hMSCs. The colony numbers in TERT-transfected hMSC clones (hMSC#3 and #4) were significantly higher than In addition, the cellular growth rates of TERT-transfected hMSC (hMSC#3 and #4) clones are higher than those of vectortransfected clones (Fig. 5) .
In vivo tumorigenic assays. TERT-transfected hMSC cells (10 2 or 10 5 ) were subcutaneously injected into NOD-scid mice and tumor development was evaluated. As shown in Table I and Fig. 6 , all mice injected with 10 5 cells of TERT-expressing hMSC clones (TERT-hMSC#3 and TERT-hMSC#4) developed tumors and 5 of 8 mice injected with 10 2 cells of these TERTexpressing hMSC clones developed tumors. In contrast, four other TERT-transfected hMSC clones (TERT-hMSC#1, #2, #5, and #6) and all the vector-transfected hMSCs, did not produce tumors after injections of 10 2 cells, although an injection of two vector-transfected hMSCs clones (vectorhMSC#2 and vector-hMSC#3) and two TERT-transfected hMSC clones (TERT-hMSC#2 and TERT-hMSC#5) did induce tumorigenesis in mice after 10 5 injection (Table Ι) . Macroscopically, tumors derived from TERT-expressing hMSCs (TERT-hMSC#3 and TERT-hMSC#4) were large and hard (Fig. 6B) , while tumors arising from cells without TERT expression were small and relatively soft (Fig. 6F) . Histological examination revealed that the former were teratocarcinomalike tumors (Fig. 6C and D) , while the latter were teratomas with several differentiated tissues, including fat and bone ( Fig. 6G and H) . Immunohistological examination revealed that the former showed TERT expression (Fig. 6E) , while the latter did not (Fig. 6I) .
Discussion
hMSCs maintain the homeostasis of bone and cartilage and are found in adult human BM. Those obtained from human in late adulthood still exhibit osteogenic potency (15) . Thus, it is thought that hMSCs maintain lifetime self-renewal and differentiation capacity in vivo. However, several previous studies showed that the self-renewal potency of hMSCs is decreased by long-term culture in vitro (16) (17) (18) and that FGF-2 expands multipotent hMSCs with high proliferation potential (7). It is also possible that cellular senescence in hMSCs, which might be induced by TGF-β1 and increased levels of CDk inhibitors (p16  INK4a , p21   Cip1 , and p53), is reversed by FGF-2 (19, 20) . In the present study, six FGF(+) hMSC clones were cultureable for more than one year. The mechanism by which they were immortalized is still unknown, but these cell lines retain mutipotential differentiation activity. Thus, these human BM-derived MSCs can be cultured long-term in vitro, without losing their peculiar morphological, phenotypical, and functional characteristics and might become a universal source of cells for regenerative therapies. To elucidate the mechanism of immortalization, we analyzed telomere and telomerase in these immortalized hMSCs. Long telomere lengths (approximately 40 kb) were maintained without detectable telomerase activity. Thus, telomeres in these cells are maintained by ALT, which is characterized phenotypically by long and heterogeneous telomeres. ALT-activated tumors, relatively low in human malignancies, are sometimes of mesenchymal origin, and there is evidence to suggest an MSC origin for ALT immortalization in cell lines (21) . Therefore, ALT activation of these hMSCs might be characteristic of the mesenchymal origin cells. Telomerase activity and TERT expression were repressed in our hMSCs clones, even after the cells acquired immortalization. Their repression occurred in ALT-activated hMSCs, although there were several instances of hMSCs with telomerase activation to maintain telomere length for acquiring immortalization (20, 22) . Thus, two mechanisms based on the presence of either telomerase or ALT expression influence hMSC immortalization. Several reports of hMSC immortalization via TERT transduction, and the present data describing immortalization in FGF-2-expanded hMSCs via an ALT mechanism, support this discrimination. However, the mechanism of these activation on hMSCs in vivo remains unknown and the effects of both factors at the same time on hMSCs are unclear.
In the present study, human BM-derived MSCs could be cultured long-term in medium with FGF-2 without losing their peculiar morphological, phenotypical, and functional characteristics. TERT-transfected hMSCs retain the potential of chondrogenic, osteogenic, and adipogenic differentiation but display an increased capacity of colony formation in soft agar and increased tumorigenicity in immunodeficient mice. The transduction of TERT obviously induces the malignant phenotypes of hMSCs, which can also be cultured long-term in vitro, without loss of their morphological, phenotypical, and functional characteristics. In these TERT-transfected clones, hMSCs that express TERT exhibit malignant phenotypes, while those that lose TERT expression do not. Therefore, TErT transduction might play a significant role in the malignant transformation of hMSCs. Although telomerase activity was upregulated in TERT-transfected clones, telomere lengths were as long as those in ALT-activated clones before TERT transfection, indicating that transduced TERT might play a role in malignant transformation other than telomere maintenance. Recent reports suggest that TERT is active in a wide variety of functions, and is a component of RNAdependent RNA polymerase (23) . Therefore, activation of TERT might correlate with malignant transformation of hMSCs. TERT-transduced hMSCs also have extended replicative capacity while maintaining their differential capacity (22, 24) . Therefore, since our hMSCs were immortalized by ALT after FGF-2 treatment before TERT transfection, other factors might be necessary for malignant transformation of normal hMSCs.
In conclusion, human BM-derived MSCs can be cultured long-term in vitro by ALT telomere maintenance without losing their morphological, phenotypical, and functional characteristics. Moreover, these cells are malignantly transformed by TERT transduction, suggesting that activation of TERT is correlated with cancer formation of hMSCs. These cells might be a model for cancer stem cells if they derive from normal tissue stem cells. Further studies are necessary to fully understand the mechanism of malignant transformation by TERT transduction and any correlation with cancer stem cells. Our results support the concept that the biological properties of hMSCs after in vitro expansion remain suitable for use in cell therapy approaches; however, considering the interest in the utilization of hMSCs in several fields of medicine and the potential risk of developing malignant transformation during the expansion period, we strongly recommended the establishment of a suitable test for phenotypic, functional, and genetic characteristics of hMSCs after in vitro expansion to further guarantee the safety of the patient. 
